Actively Recruiting

Phase 1
Age: 18Years - 85Years
All Genders
NCT04842812

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-25

40

Participants Needed

1

Research Sites

730 weeks

Total Duration

On this page

Sponsors

S

Second Affiliated Hospital of Guangzhou Medical University

Lead Sponsor

G

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

CONDITIONS

Official Title

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with advanced cancers that have not responded to current therapies
  • Life expectancy greater than 12 weeks
  • Adequate heart, lung, liver, and kidney functions
  • Ability to undergo tumor biopsy or cancerous effusion collection
  • Provided informed consent understood and signed by patient or guardian
Not Eligible

You will not qualify if you...

  • Previous gene therapy treatment
  • Severe virus infections such as HBV, HCV, HIV, or known HIV positivity
  • Active infections caused by bacteria, viruses, or fungi
  • Other severe diseases deemed inappropriate by investigators
  • Pregnant or breastfeeding women
  • Receiving systemic steroid treatment at or above 0.5 mg prednisone equivalent/kg/day
  • Other conditions deemed inappropriate by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, China, 510260

Actively Recruiting

Loading map...

Research Team

Z

Zhenfeng Zhang, MD, PhD

CONTACT

B

Bingjia He, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here